| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.GTC.2005.02.008 |
| P698 | PubMed publication ID | 15862929 |
| P50 | author | Nicholas Talley | Q7026286 |
| P2093 | author name string | Filippo Cremonini | |
| P433 | issue | 2 | |
| P921 | main subject | epidemiology | Q133805 |
| irritable bowel syndrome | Q838966 | ||
| P304 | page(s) | 189-204 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Gastroenterology Clinics of North America | Q15756082 |
| P1476 | title | Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors | |
| P478 | volume | 34 |
| Q64953460 | A Comprehensive Look at Irritable Bowel Syndrome and its Associated Factors Considering the Rome IV Criteria: A Penalized Smoothly Clipped Absolute Deviation Regression Approach in the Pars Cohort Study. |
| Q47934836 | A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. |
| Q39247774 | A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. |
| Q34416297 | A role for the gut microbiota in IBS. |
| Q34999672 | A serotonin transporter gene (SLC6A4) polymorphism is associated with reduced risk of irritable bowel syndrome in American and Asian population: a meta-analysis |
| Q36060265 | An Initial Attack of Urinary Stone Disease Is Associated with an Increased Risk of Developing New-Onset Irritable Bowel Syndrome: Nationwide Population-Based Study |
| Q24631963 | Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome |
| Q39335444 | Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial |
| Q37504598 | Anxiety, depression and distress among irritable bowel syndrome and their subtypes: An epidemiological population based study |
| Q48462014 | Asking the why questions: a career in science |
| Q37346021 | Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome? |
| Q47209693 | Clinical-Pathological Conference Series from the Medical University of Graz : Case No 153: A 55-year-old woman with atypical multiple sclerosis and irritable bowel syndrome |
| Q39154158 | Cross-cultural and Psychological issues in Irritable Bowel Syndrome |
| Q37800671 | Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome |
| Q37438547 | Current and novel therapeutic options for irritable bowel syndrome management |
| Q37652847 | Development and pilot testing of an integrated, web-based self-management program for irritable bowel syndrome (IBS). |
| Q39669288 | Dietary patterns and prevalence of irritable bowel syndrome in Iranian adults. |
| Q51530376 | Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults. |
| Q37279058 | Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions |
| Q37058880 | Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review |
| Q37777216 | Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression |
| Q39268498 | Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial |
| Q40775494 | Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multicenter study in Japan |
| Q35861085 | Family history of mental illness or alcohol abuse and the irritable bowel syndrome |
| Q57075063 | First-in-Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers |
| Q37134568 | Functional gastrointestinal disorders as a public health problem |
| Q36529707 | Gastrointestinal Symptoms of Patients with Fabry Disease |
| Q36531260 | Gastrointestinal microflora: probiotics |
| Q37569190 | Health Related Quality of Life in Iranian Patients With Irritable Bowel Syndrome: Reliability and Validity of the Persian Version of the IBS-QOL. |
| Q36917161 | Insights into normal and disordered bowel habits from bowel diaries |
| Q24601623 | Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes |
| Q36101911 | Irritable Bowel Syndrome in Iran: SEPAHAN Systematic Review No. 1 |
| Q85631567 | Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders? |
| Q44552469 | Irritable bowel syndrome and other gastrointestinal disorders: evaluating self-medication in an Asian community setting |
| Q36514156 | Irritable bowel syndrome: recent and novel therapeutic approaches |
| Q48690731 | Is Major Depression a Risk for Bladder, Bowel, and Sexual Dysfunction? |
| Q34274100 | Ischemic hypersensitivity in irritable bowel syndrome patients. |
| Q39756148 | Low social class is linked to upper gastrointestinal symptoms in an Australian sample of urban adults |
| Q45189883 | Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. |
| Q37156630 | Meta-analysis of probiotics for the treatment of irritable bowel syndrome |
| Q64915328 | Neuromuscular electrical stimulation as an adjunctive therapy to drotaverine hydrochloride for treating patients with diarrhea-predominant irritable bowel syndrome: A retrospective study. |
| Q43062026 | New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline |
| Q38747166 | Novel pharmacological therapies for irritable bowel syndrome. |
| Q48313903 | Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. |
| Q37799433 | Pathogenic Factors Involved in the Development of Irritable Bowel Syndrome: Focus on a Microbial Role |
| Q58601492 | Physical activity in relation to irritable bowel syndrome among Iranian adults |
| Q79890359 | Post-infectious irritable bowel syndrome |
| Q34660809 | Postinfectious irritable bowel syndrome: a long-term consequence of bacterial gastroenteritis |
| Q36143939 | Prevalence of functional bowel disorders and faecal incontinence: an Australian primary care survey |
| Q37542854 | Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian University: an electronic survey |
| Q35555727 | Prevalence of restless legs syndrome in patients with irritable bowel syndrome |
| Q24244086 | Probiotic agents for the treatment of diarrhoea-predominant irritable bowel syndrome |
| Q33730572 | Probiotic treatment of irritable bowel syndrome in children |
| Q34637436 | Probiotics in the gastrointestinal diseases of the elderly. |
| Q49213442 | Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome |
| Q38197845 | Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome |
| Q36526204 | Self-reported physical health, mental health, and comorbid diseases among women with irritable bowel syndrome, fibromyalgia, or both compared with healthy control respondents |
| Q89089670 | Sex differences in NSAID-induced perturbation of human intestinal barrier function and microbiota |
| Q50500325 | Sex differences in stress-induced visceral hypersensitivity following early life adversity: a two hit model. |
| Q36991372 | Sex-related differences in pain behaviors following three early life stress paradigms |
| Q35865356 | Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome |
| Q37097644 | Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population |
| Q21261900 | Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? |
| Q43096285 | State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. |
| Q42967808 | Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? |
| Q43267055 | Tegaserod in the treatment of irritable bowel syndrome with constipation |
| Q36751990 | The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease |
| Q39337639 | The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients |
| Q34072873 | The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial |
| Q34031406 | The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial |
| Q35855576 | The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study |
| Q37577760 | The epidemiology of irritable bowel syndrome |
| Q41078599 | The global impact of IBS: time to think about IBS-specific models of care? |
| Q27024239 | The quest for biomarkers in IBS-where should it lead us? |
| Q34118117 | The serotonin transporter polymorphism rs25531 is associated with irritable bowel syndrome |
| Q37938817 | The spectrum of functional gastrointestinal disorders in a tertiary referral clinic in Ireland |
| Q37156627 | Updates on treatment of irritable bowel syndrome |
Search more.